Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-04

Clinical Trial Update: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BI 706321 in combination with ustekinumab for Crohn's disease was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 706321
  • USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Crohn Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-09-04